Skip to content

Multicenter observation of the effect of press-needle for improving visual function and eye’s blood circulation of glaucoma with controlled IOP

Multicenter observation of the effect of press-needle for improving visual function and eye’s blood circulation of glaucoma with controlled IOP

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067862
Enrollment
Unknown
Registered
2023-01-29
Start date
2023-02-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

experimental group:press-needle
placebo group:Comfort needle

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary open-angle glaucoma (POAG): Open anterior chamber angle, pathologic high intraocular pressure (HIOP) [24 h peak IOP > 21 mmHg (1 mmHg = 0.133 kPa)], characteristic glaucomatous neuropathy (retinal nerve fiber layer defect, RNFLD or optic disc chang), and/or visual field loss, exclusion of other causes result in HIOP, only one eye from each patient will be chosen; 2. Have a visual field defect that could be evaluated by standard automated perimetry (reliability factor = 0.3; 6. Aged 18-75 years; 7. Be in a conscious status and able to cooperate with the examination and treatment; 8. Be willing to take part in the study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Poorly controlled IOP ( 18 mmHg) accompanied by thin filtering cystic bleb or bleb leakage; 2. Other macular degeneration, cataract, proliferative diabetic retinopathy and retinal vascular occlusion or other diseases might cause visual field loss; 3. People who take other medications and other treatments during treatmentpregnancy or lactation; 4. Pregnant or lactating patients; 5. Abnormal severe primary hepatic or renal or serious systemic diseases such as heart diseases, primary hypertension, diabetes mellitus, or gastric ulcer; 6. An allergic history to the ingredients of Press-needle or mecobalamin tablets; 7. Poor treatment compliance, unable to follow up regularly.

Design outcomes

Primary

MeasureTime frame
Mean change in best corrected visual acuity (BCVA);Visual field detection;Optical Coherence Tomography Angiography;

Secondary

MeasureTime frame
intraocular pressure;color Doppler flow imaging;Change in the number of patients with different grades of TCM symptoms;

Countries

China

Contacts

Public ContactHongji Liu

Mianyang Central Hospital

635921500@qq.com+86 15729639202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026